Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity (vol 117, 105447, 2021)

被引：0
|
作者：
Li, Ling [1 ]
Wu, Yinrong [1 ]
Yang, Zichao [1 ]
Xu, Chenglong [1 ]
Zhao, Huiting [1 ]
Liu, Jin [1 ]
Chen, Jingxuan [1 ]
Chen, Jianjun [1 ]
机构：
[1] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China
来源：
BIOORGANIC CHEMISTRY | 2024年 / 150卷
关键词：
D O I：
10.1016/j.bioorg.2024.107616
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor
    Maddess, Matthew L.
    Sloman, David L.
    Ma, Xiaoshen
    Palani, Anandan
    Stoeck, Alexander
    Sather, Aaron C.
    Solban, Nicolas
    Duggal, Ruchia
    Ballard, Jeanine
    Munsell, Erik V.
    Chen, Lin-Chi
    Han, Yongxin
    Miller, Richard
    Gathiaka, Symon
    Brynczka, Christopher
    Li, Hongming
    Yang, Ruojing
    Brynczka, Christopher
    Day, Phil
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [22] A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
    Murciano-Goroff, Yonina R.
    Heist, Rebecca S.
    Kuboki, Yasutoshi
    Koyama, Takafumi
    Ammakkanavar, Natraj Reddy
    Hollebecque, Antoine
    Patnaik, Amita
    Shimizu, Toshio
    Spira, Alexander I.
    Nagasaka, Misako
    Han, Ji-Youn
    Iams, Wade Thomas
    Deming, Dustin
    Call, Justin
    Cassier, Philippe
    Han, Sae-Won
    Chu, Quincy Siu-Chung
    Cosman, Rasha
    Durm, Gregory
    Burns, Timothy
    Willard, Melinda D.
    Liu, Shiyao
    Callies, Sophie
    Balar, Arjun V.
    Sabari, Joshua K.
    CANCER RESEARCH, 2023, 83 (08)
  • [23] Discovery of potent PROTAC degraders of KRASG12C based on a reversible non-covalent KRAS binder
    Zhang, Z.
    Zhai, W.
    Chen, H.
    Wang, L.
    Liu, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S14 - S14
  • [24] Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
    Fell, Jay B.
    Fischer, John P.
    Baer, Brian R.
    Ballard, Joshua
    Blake, James F.
    Bouhana, Karyn
    Brandhuber, Barbara J.
    Briere, David M.
    Burgess, Laurence E.
    Burkard, Michael R.
    Chiang, Harrah
    Chicarelli, Mark J.
    Davidson, Kevin
    Gaudino, John J.
    Hallin, Jill
    Hanson, Lauren
    Hee, Kenneth
    Hicken, Erik J.
    Hinklin, Ronald J.
    Marx, Matthew A.
    Mejia, Macedonio J.
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony P.
    Vigers, Guy P.
    Zecca, Henry
    Christensen, James G.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (12): : 1230 - 1234
  • [25] Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.
    Heist, Rebecca Suk
    Koyama, Takafumi
    Murciano-Goroff, Yonina R.
    Hollebecque, Antoine
    Cassier, Philippe Alexandre
    Han, Ji-Youn
    Tosi, Diego
    Sacher, Adrian G.
    Burns, Timothy F.
    Spira, Alexander I.
    Gomez-Roca, Carlos A.
    Shimizu, Toshio
    Ammakkanavar, Natraj Reddy
    Sabari, Joshua K.
    Nagasaka, Misako
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Kuboki, Yasutoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Use of chemotype evolution to discover novel, potent, irreversible inhibitors of the oncogenic G12C mutant form of KRAS
    Erlanson, Daniel
    Arvedson, Tara
    Cee, Victor
    Fucini, Ray
    Hansen, Stig
    Iwig, Jeff
    Jeong, Joon Won
    McCarter, John
    Sabet, Sudi
    Sawayama, Andrew
    Sethofer, Steven
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [27] Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects
    Song, Zhendong
    Lou, Linlin
    Fan, Guangjin
    Liu, Lu
    Ge, Yang
    Liu, He
    Chan, Albert S. C.
    Zhang, Xiaolei
    Xiong, Xiao-Feng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 245
  • [28] Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry
    Tran, John C.
    Hunsaker, Thomas
    Bell, Christina
    Ma, Taylur P.
    Chan, Emily
    Larrocha, Pablo Saenz-Lopez
    Homyk, Kelsey
    Liu, Liling
    La, Hank
    Mao, Jialin
    de la Cruz, Cecile C.
    Yu, Kebing
    Beresini, Maureen
    Forrest, William F.
    Xiao, Yang
    Jang, Anne
    Samus, Natalia
    Stesco, Nicholas Dupuis
    Mentinova, Marija
    Parent, Stephane
    Pottiez, Gwenael
    Schirm, Michael
    Purkey, Hans E.
    Liu, Yichin
    Merchant, Mark
    ANALYTICAL CHEMISTRY, 2023, 95 (11) : 4834 - 4839
  • [29] RNA-based gene alteration and expression analysis in NSCLC with known KRAS G12C status
    Moes-Sosnowska, Joanna
    Lechowicz, Urszula
    Pelc, Magdalena
    Szpechcinski, Adam
    Skronska, Paulina
    Rozy, Adriana
    Zdral, Aneta
    Polaczek, Mateusz
    Wojda, Emil
    Szolkowska, Malgorzata
    Orlowski, Tadeusz
    Sliwinski, Pawel
    Langfort, Renata
    Chorostowska-Wynimko, Joanna
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 1280 - 1280
  • [30] Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagement kinetics
    Zhang, J.
    Lu, J.
    Zheng, Z.
    Lu, J.
    Wang, A.
    Wang, J.
    Chen, J.
    Rui, H.
    Chen, C.
    Chen, G.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S74 - S74
12345